PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer.
Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world’s largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providing patients with neurosurgical care.
“Dr. Turner’s extensive medical and clinical experience and expertise will be significant assets to Integra as we strengthen our focus on building robust clinical evidence,” said Mojdeh Poul, president and chief executive officer, Integra LifeSciences. “His proven leadership and passion for advancing safety and quality will help us continue to deliver innovative solutions and transform patient care for the millions around the world.”
Prior to joining Integra, Dr. Turner held various leadership roles at Siemens Healthineers, including his most recent position as the chief medical officer for Siemens Endovascular Robotics. Prior to this, he was a medical director for Cerenovus, a Johnson & Johnson MedTech company. Additionally, Dr. Turner served as the program director of the neurosurgery residency program and was the chief of neuroscience (neurological surgery, neurology, and ENT) at the Medical University of South Carolina.
“I am excited to be joining Integra, an organization deeply committed to providing best-in-class, evidence-based products that help restore patient lives,” said Dr. Raymond Turner. “I look forward to working closely with both the Integra team and our healthcare partners to improve patient outcomes and uphold the highest standards of care.”
Dr. Turner served as a practicing surgeon at PRISMA Health and most recently, at Intermountain Health in Billings, Montana. He currently serves as an examiner for the American Board of Neurological Surgery.
Dr. Turner completed his undergraduate degree in biology at Sacred Heart University in Connecticut. He obtained his medical degree at Karol Marcinkowski University of Medical Sciences in Poznan, Poland. Dr. Turner completed his residency in neurological surgery and his fellowship in endovascular neurosurgery at the Cleveland Clinic. He has authored more than 150 peer-reviewed publications and has been involved in more than 70 pre-clinical and clinical research studies.
About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership medical technology brands. For the latest news and information about Integra and its products, please visit www.integralife.com.
Investor Relations:
Chris Ward
(609) 772-7736
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Laurene Isip
(609) 208-8121
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$14.61 |
Daily Change: | 0.38 2.67 |
Daily Volume: | 1,043,764 |
Market Cap: | US$1.140B |
October 08, 2025 August 29, 2025 July 02, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load